Previous close | 1.3500 |
Open | 1.7000 |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 540.00 |
Expiry date | 2025-01-17 |
Day's range | 1.3500 - 1.7000 |
Contract range | N/A |
Volume | |
Open interest | 69 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?